COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series

Sharon L. Walmsley; Leah Szadkowski; Bradly Wouters; Rosemarie Clarke; Karen Colwill; Paula Rochon; Michael Brudno; Rizanni Ravindran; Janet Raboud; Allison McGeer; Amit Oza; Christopher Graham; Amanda Silva; Dorin Manase; Peter Maksymowsky; Laura Parente; Roaya Monica Dayam; Jacqueline Simpson; Adrian Pasculescu; Anne-Claude Gingras

iScience (Apr 2023)

COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series

Sharon L. Walmsley,
Leah Szadkowski,
Bradly Wouters,
Rosemarie Clarke,
Karen Colwill,
Paula Rochon,
Michael Brudno,
Rizanni Ravindran,
Janet Raboud,
Allison McGeer,
Amit Oza,
Christopher Graham,
Amanda Silva,
Dorin Manase,
Peter Maksymowsky,
Laura Parente,
Roaya Monica Dayam,
Jacqueline Simpson,
Adrian Pasculescu,
Anne-Claude Gingras

Affiliations

Sharon L. Walmsley: Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada; Toronto General Hospital Research Institute, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Corresponding author
Leah Szadkowski: Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Bradly Wouters: Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Rosemarie Clarke: Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada
Karen Colwill: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Paula Rochon: Women’s College Hospital Research Institute, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Michael Brudno: Department of Computer Science, University Health Network, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Rizanni Ravindran: Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Janet Raboud: Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Allison McGeer: Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Amit Oza: Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Christopher Graham: Trillium Health Partners, Department of Medicine, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Amanda Silva: Department of BioInformatics, University Health Network, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Dorin Manase: Department of BioInformatics, University Health Network, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Peter Maksymowsky: Department of BioInformatics, University Health Network, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Laura Parente: Health Care Human Factors, University Health Network, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Roaya Monica Dayam: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Jacqueline Simpson: Health Care Human Factors, University Health Network, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Adrian Pasculescu: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
Anne-Claude Gingras: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada

Journal volume & issue: Vol. 26, no. 4
p. 106506

Abstract

Read online

Summary: We report a decentralized prospective cohort study of self-reported adverse events and antibody responses to COVID vaccines derived from dried blood spots. Data are presented for 911 older (aged >70 years) and 375 younger (30–50 years) recruits to 48 weeks after the primary vaccine series. After a single vaccine, 83% younger and 45% older participants had overall seropositivity (p < 0.0001) increasing to 100/98% with the second dose, respectively (p = 0.084). A cancer diagnosis (p = 0.009), no mRNA-1273 vaccine doses (p <0 .0001), and older age (p <0 .0001) predicted lower responses. Antibody levels declined in both cohorts at 12 and 24 weeks increasing with booster doses. At 48 weeks, for participants with 3 vaccine doses, the median antibody levels were higher in the older cohort (p = 0.04) with any dose of mRNA-1273 (p <0 .0001) and with COVID infection (p <0 .001). The vaccines were well tolerated. Breakthrough COVID infections were uncommon (16% older cohort, 29% younger cohort; p < 0.0001) and mild.

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords